Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. There pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. There pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response
Recent Articles
- Sisecam Reports Strong Q1 2025 Results Amidst Challenges
- Aslan Energy Capital's Ambitious Solar Initiative for Hydrogen
- IPC and Open Lake Technology Partner to Enhance Compliance
- Promising Data for EnteroBiotix's EBX-102 in Liver Health
- Unlocking Insights from the 2025 Global ETF Survey Report
- XPENG and Plugsurfing Team Up for an Expanded Charging Network
- Hi-View Resources Expands Claims in Toodoggone's Mining Hub
- GTCR Partners with JMG Group to Propel Insurance Growth
- GTCR's Strategic Acquisition of JMG Group Signals Growth
- Join BioArctic's Exciting Q1 2025 Financial Presentation
- Bullish Shapes Future of Crypto with Groundbreaking Regulation
- Ogury Partners with 51toCarbonZero to Achieve Net Zero Goals
- King Street Makes Bold Move with €400 Million for Room00
- Siteimprove Launches Innovative AI SEO Intelligence Suite
- SIS, LLC Welcomes Andrew Rowney as New Sales Director
- Fangzhou Inc. Revolutionizes Healthcare at 2025 Conference
- King Street Capital Commits €400 Million to Room00 Group Growth
- The Rise of Collaborative Global Creations in Chinese Literature
- Join BioArctic's Upcoming Presentation for Q1 Report Insights
- Exploring the Future of the Global Wheelchair Market Growth
- Mobilize and Autostrade Join Forces for Green Mobility Growth
- Syensqo Unveils New Segment Reporting Structure for Growth
- Hansa Biopharma Welcomes Maria Törnsén as New COO and President
- Hansa Biopharma Welcomes Maria Törnsén as COO and President
- SciBase's Strong Growth in Q1 2025: Key Highlights and Future
- PingProperties Enhances Operations with Yardi's Cloud Solutions
- PingProperties Chooses Yardi for Enhanced Real Estate Efficiency
- Aker ASA's Strategic Move Enhances Real Estate Portfolio Growth
- Kvantify Partners with Gefion for Advanced Quantum Simulations
- Elevate Your Clean Routine This Shedding Season with Jimmy
- Hexagon Agility Secures Major Contracts for CNG Truck Systems
- EG 427's Innovations in Neurology Using Advanced Vector Technology
- Exploring the Future of Thin Film and Printed Battery Market Growth
- Strategic Partnership Transforms Thailand’s Capital Markets with Nasdaq
- ING's Strategic Share Buyback Progress Reflects Value Growth
- Exciting Exploration Developments for Amaroq Minerals in 2024
- NB Private Equity Partners Announces Strategic Share Buyback Plan
- Quadient and Nuvei Join Forces to Transform Payment Solutions
- Foresight Group's Recent Share Buyback Enhances Investor Trust
- RIBER Announces Significant MBE 412 System Order from Australia
- HER-096 Clinical Trial Updates: Paving the Way for Parkinson's Care
- Antaisolar Expands Presence with Innovative PV Solutions
- Oracle Partners with seQure for Advanced Cybersecurity Solutions
- Transforming African Connectivity with Q-KON and Rivada's Partnership
- Transform Your Cleaning Routine with the Jimmy BX7 Pro Max
- Understanding the 2024 Dividend Payout Procedures Clearly
- Shanghai Introduces Ten Strategic Missions to Boost Business Climate
- Galapagos Navigates Strategic Changes Amid Leadership Transition
- Nilfisk's Q1 Report: Insights into Financial Performance Ahead
- Aalberts Advances Share Buyback Program with Significant Activity